This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Astra Zeneca U.k. Limited, Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron, Xentech Sas. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 110 
1 out of 7 
1 out of 1 Years Active: 2024
Title: Marta Castroviejo Bermejo: Innovator in Cancer Treatment
Introduction
Marta Castroviejo Bermejo is a prominent inventor based in Logroño, Spain. She has made significant contributions to the field of oncology through her innovative methods for cancer treatment. Her work focuses on improving the sensitivity of cancer patients to anti-cancer therapies.
Latest Patents
Marta holds a patent for her invention titled "Methods based on the detection of RAD51 foci in tumor cells." This method allows for the determination of whether a subject diagnosed with cancer is sensitive or resistant to anti-cancer treatment. The invention is based on assessing the level of cells with RAD51 foci in a sample of tumor cells isolated from the subject, provided that the subject has not received specific chemotherapy treatments within 24 hours prior to sample isolation.
Career Highlights
Throughout her career, Marta has worked with notable organizations, including the Fundació Privada Institut d'Investigació Oncològica de Vall Hebron and AstraZeneca UK Limited. Her experience in these institutions has contributed to her expertise in cancer research and treatment methodologies.
Collaborations
Marta has collaborated with esteemed colleagues such as Violeta Serra Elizalde and Judith Balmaña Gelpi. These partnerships have further enhanced her research and development efforts in the field of oncology.
Conclusion
Marta Castroviejo Bermejo is a trailblazer in cancer treatment innovation, with her patented methods offering new hope for patients. Her dedication to advancing cancer research continues to make a significant impact in the medical community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile